HK1178517A1 - Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h- pyrrolo-pyridin-yl)-methanones and synthesis thereof [4[4-(5--2--)--1-]-(1h-)- - Google Patents

Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h- pyrrolo-pyridin-yl)-methanones and synthesis thereof [4[4-(5--2--)--1-]-(1h-)-

Info

Publication number
HK1178517A1
HK1178517A1 HK13105265.2A HK13105265A HK1178517A1 HK 1178517 A1 HK1178517 A1 HK 1178517A1 HK 13105265 A HK13105265 A HK 13105265A HK 1178517 A1 HK1178517 A1 HK 1178517A1
Authority
HK
Hong Kong
Prior art keywords
methanones
pyrrolo
piperidin
aminomethyl
prodrugs
Prior art date
Application number
HK13105265.2A
Other languages
English (en)
Chinese (zh)
Inventor
Yong Mi Choi-Sledeski
Gregory B Poli
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1178517A1 publication Critical patent/HK1178517A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
HK13105265.2A 2009-12-23 2013-04-30 Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h- pyrrolo-pyridin-yl)-methanones and synthesis thereof [4[4-(5--2--)--1-]-(1h-)- HK1178517A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28953709P 2009-12-23 2009-12-23
FR1057197 2010-09-10
PCT/US2010/061434 WO2011079095A1 (en) 2009-12-23 2010-12-21 Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof

Publications (1)

Publication Number Publication Date
HK1178517A1 true HK1178517A1 (en) 2013-09-13

Family

ID=44246892

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13105265.2A HK1178517A1 (en) 2009-12-23 2013-04-30 Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h- pyrrolo-pyridin-yl)-methanones and synthesis thereof [4[4-(5--2--)--1-]-(1h-)-

Country Status (26)

Country Link
US (1) US8710080B2 (da)
EP (1) EP2516418B1 (da)
JP (1) JP2013515732A (da)
KR (1) KR20120106824A (da)
CN (1) CN102791702A (da)
AR (1) AR079661A1 (da)
AU (1) AU2010333772B2 (da)
BR (1) BR112012014860A2 (da)
CA (1) CA2784891A1 (da)
CY (1) CY1115445T1 (da)
DK (1) DK2516418T3 (da)
ES (1) ES2481790T3 (da)
HK (1) HK1178517A1 (da)
HR (1) HRP20140607T1 (da)
IL (1) IL220380A0 (da)
MX (1) MX2012006739A (da)
MY (1) MY155980A (da)
PL (1) PL2516418T3 (da)
PT (1) PT2516418E (da)
RS (1) RS53456B (da)
RU (1) RU2012131146A (da)
SG (1) SG181501A1 (da)
SI (1) SI2516418T1 (da)
TW (1) TW201125860A (da)
UY (1) UY33134A (da)
WO (1) WO2011079095A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53456B (en) 2009-12-23 2014-12-31 Sanofi [4 [4- (5-AMINOMETHYL-2-FLUOR-PHENYL) -PIPERIDIN-1-IL] - (1H-Pyrrolo-pyridin-IL) -METHANONE AND THEIR SYNTHESIS
MX2012006805A (es) * 2009-12-23 2012-07-10 Sanofi Sa Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4879119A (en) 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE107176T1 (de) 1989-12-04 1994-07-15 Searle & Co System zur transdermalen albuterol applikation.
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
GB0012362D0 (en) 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
CA2409827C (en) * 2000-05-22 2010-06-01 Aventis Pharmaceuticals Products Inc. Arylmethylamine derivatives for use as tryptase inhibitors
PT2367812E (pt) * 2008-08-22 2016-01-20 Sanofi Sa [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]metanona como um inibidor da triptase de mastócitos
RS53456B (en) 2009-12-23 2014-12-31 Sanofi [4 [4- (5-AMINOMETHYL-2-FLUOR-PHENYL) -PIPERIDIN-1-IL] - (1H-Pyrrolo-pyridin-IL) -METHANONE AND THEIR SYNTHESIS

Also Published As

Publication number Publication date
HRP20140607T1 (hr) 2014-09-26
ES2481790T3 (es) 2014-07-31
EP2516418B1 (en) 2014-05-14
DK2516418T3 (da) 2014-08-11
IL220380A0 (en) 2012-08-30
PL2516418T3 (pl) 2014-10-31
RS53456B (en) 2014-12-31
US20120238573A1 (en) 2012-09-20
CY1115445T1 (el) 2017-01-04
AU2010333772B2 (en) 2016-07-14
BR112012014860A2 (pt) 2016-03-29
MY155980A (en) 2015-12-31
KR20120106824A (ko) 2012-09-26
UY33134A (es) 2011-07-29
CN102791702A (zh) 2012-11-21
MX2012006739A (es) 2012-06-28
EP2516418A1 (en) 2012-10-31
PT2516418E (pt) 2014-07-18
AU2010333772A1 (en) 2012-07-05
AR079661A1 (es) 2012-02-08
CA2784891A1 (en) 2011-06-30
TW201125860A (en) 2011-08-01
US8710080B2 (en) 2014-04-29
JP2013515732A (ja) 2013-05-09
WO2011079095A1 (en) 2011-06-30
SG181501A1 (en) 2012-07-30
RU2012131146A (ru) 2014-02-10
SI2516418T1 (sl) 2014-08-29

Similar Documents

Publication Publication Date Title
ZA201107336B (en) Synthesis of 2'-o-fucosyllactose
EP2421867A4 (en) PANELID INHIBITORS OF JANUS KINASE 3
ZA201200054B (en) Therapeutic compounds and compositions
EP2473043A4 (en) ORAL CARE PROCESSES AND COMPOSITIONS WITH CHITOSANE DERIVATIVE COMPONENTS
EP2488172A4 (en) DENDRIMER COMPOSITION AND METHOD FOR THEIR SYNTHESIS
HK1167785A1 (en) Transgenic rice event 17314 and methods of use thereof 17314
PL2448581T3 (pl) Kompozycje terapeutyczne i odnośne sposoby ich stosowania
EP2454954A4 (en) TOBACCO PRODUCT FOR ORAL USE
ZA201107847B (en) Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof
EP2443943A4 (en) TOBACCO PRODUCT FOR ORAL USE
IL218212A0 (en) Therapeutic methods and compositions
ZA201204672B (en) Oral care compositions
IL207724A0 (en) Cns pharmaceutical compositions and methods of use
EP2443944A4 (en) ORAL CUSTOM TOBACCO PRODUCT
HRP20130395T1 (en) Treatment of melanoma
ZA201200894B (en) Synthesis and use of zsm-12
ZA201202405B (en) Crystallization of 4'-epidaunorubicin x hci
IL201766A0 (en) Compositions of (-)-e-10-oh-nt and methods for their synthesis and use
HK1178517A1 (en) Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h- pyrrolo-pyridin-yl)-methanones and synthesis thereof [4[4-(5--2--)--1-]-(1h-)-
EP2461870A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
GB0914782D0 (en) Perfluoroparacyclophane and methods of synthesis and use thereof
ZA201204530B (en) Oral care compositions and methods
ZA201105162B (en) Stereoselective synthesis of piperidine derivatives
SI2504309T1 (sl) Sinteza acetokslacetaldehida
IL206021A0 (en) Crystalline form of azelastine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181220